Stealthy opthalmalogical surgery company Clerio Vision raised $3.2 million in a new round of equity financing to support its novel surgical treatment for individuals with refractive error.
The Rochester, N.Y.-based company is developing a surgical strategy using a femtosecond laser to change the refractive index of the cornea with small pulses to noninvasively correct the issue by “writing” a corrective prescription onto the cornea, according to CrunchBase.com.
The procedure can be repeated, as it doesn’t thin the cornea, to correct vision in patients over many different iterations in their lifetime.
The stealthy company is looking to bring in another $1.8 million before closing the round, according to an SEC filing. The company has not yet stated what it will do with the funds, raised from 31 anonymous sources, and has not yet released full-information on its treatment system.
Clerio Vision has plans to begin early human studies this year, with the team being advised by Dr. Charles Munnerlyn and has received some support from the original developers of the 1st Lasik systems, according to CrunchBase.com.
The company, founded in 2014, is a spin-out from the University of Rochester, and is being headed by iCardiac Technologies founder and CIO Mikael Totterman, according to Linkedin.com.